Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimiliano Sarra

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Journal of Biomedicine & Biotechnology|July 24, 2010
Interleukin-21: a new mediator of inflammation in systemic lupus erythematosusMassimiliano Sarra, Giovanni Monteleone
Biofactors (Oxford, England)|April 5, 2013
Interleukin-21 in chronic inflammatory diseasesMassimiliano Sarra, Francesco Pallone, Giovanni Monteleone
Discovery Medicine|October 17, 2009
Interleukin-21 in T cell-mediated diseasesGiovanni Monteleone, Massimiliano Sarra, Francesco Pallone
Expert Opinion on Therapeutic Targets|March 12, 2011
Targeting interleukin-21 in inflammatory diseasesMassimiliano Sarra, Eleonora Franzè, Francesco Pallone, et al.
World Journal of Gastroenterology|August 3, 2010
Interleukin-21 triggers effector cell responses in the gutDaniela De Nitto, Massimiliano Sarra, Francesco Pallone, et al.
Inflammation & Allergy Drug Targets|April 27, 2012
Interleukin-21 in immune and allergic diseasesMassimiliano Sarra, Maria Laura Cupi, Francesco Pallone, et al.
Inflammatory Bowel Diseases|April 18, 2012
What's the next best cytokine target in IBD?Thomas T MacDonald, Paolo Biancheri, Massimiliano Sarra, et al.
Inflammatory Bowel Diseases|March 12, 2010
IL-23/IL-17 axis in IBDMassimiliano Sarra, Francesco Pallone, Thomas T Macdonald, et al.
Current Drug Targets|December 18, 2009
Targeting interleukin-21 in immune-mediated pathologiesMassimiliano Sarra, Francesco Pallone, Thomas T Macdonald, et al.
Global & Regional Health Technology Assessment|February 15, 2023
Francesco Malandrini, Cesare Borroni, Michela Meregaglia, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Journal of Biomedicine & Biotechnology|July 24, 2010
Interleukin-21: a new mediator of inflammation in systemic lupus erythematosusMassimiliano Sarra, Giovanni Monteleone
Biofactors (Oxford, England)|April 5, 2013
Interleukin-21 in chronic inflammatory diseasesMassimiliano Sarra, Francesco Pallone, Giovanni Monteleone
Discovery Medicine|October 17, 2009
Interleukin-21 in T cell-mediated diseasesGiovanni Monteleone, Massimiliano Sarra, Francesco Pallone
Expert Opinion on Therapeutic Targets|March 12, 2011
Targeting interleukin-21 in inflammatory diseasesMassimiliano Sarra, Eleonora Franzè, Francesco Pallone, et al.
World Journal of Gastroenterology|August 3, 2010
Interleukin-21 triggers effector cell responses in the gutDaniela De Nitto, Massimiliano Sarra, Francesco Pallone, et al.
Inflammation & Allergy Drug Targets|April 27, 2012
Interleukin-21 in immune and allergic diseasesMassimiliano Sarra, Maria Laura Cupi, Francesco Pallone, et al.
Inflammatory Bowel Diseases|April 18, 2012
What's the next best cytokine target in IBD?Thomas T MacDonald, Paolo Biancheri, Massimiliano Sarra, et al.
Inflammatory Bowel Diseases|March 12, 2010
IL-23/IL-17 axis in IBDMassimiliano Sarra, Francesco Pallone, Thomas T Macdonald, et al.
Current Drug Targets|December 18, 2009
Targeting interleukin-21 in immune-mediated pathologiesMassimiliano Sarra, Francesco Pallone, Thomas T Macdonald, et al.
Global & Regional Health Technology Assessment|February 15, 2023
Francesco Malandrini, Cesare Borroni, Michela Meregaglia, et al.
Pageof 4